These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 5300360)

  • 1. Clinical and pharmacological effects of monoamine precursors or haloperidol in chronic schizophrenia.
    Persson T; Roos BE
    Nature; 1968 Mar; 217(5131):854. PubMed ID: 5300360
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 3. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
    Rüther E; Schilkrut R; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):33-6. PubMed ID: 981320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype of affective psychoses classified by response on amineprecursors and monoamine metabolism.
    Fujiwara J; Otsuki S
    Folia Psychiatr Neurol Jpn; 1974; 28(2):93-100. PubMed ID: 4212375
    [No Abstract]   [Full Text] [Related]  

  • 6. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of 5-hydroxytryptophan on sleep of a patient with a brain-stem lesion.
    Guilleminault C; Cathala JP; Castaigne P
    Electroencephalogr Clin Neurophysiol; 1973 Feb; 34(2):177-84. PubMed ID: 4119531
    [No Abstract]   [Full Text] [Related]  

  • 8. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease. Modification by 5-hydroxytryptophan.
    Chase TN; Ng LK; Watanabe AM
    Neurology; 1972 May; 22(5):479-84. PubMed ID: 4563493
    [No Abstract]   [Full Text] [Related]  

  • 10. Overview of pharmacological approaches to therapy for Tourette syndrome.
    van Woert MH; Rosenbaum D; Enna SJ
    Adv Neurol; 1982; 35():369-75. PubMed ID: 6183950
    [No Abstract]   [Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa.
    Mendell JR; Chase TN; Engel WK
    Arch Neurol; 1971 Oct; 25(4):320-5. PubMed ID: 5110126
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemical and pharmacologic studies of dystonia.
    Chase TN
    Neurology; 1970 Nov; 20(11):122-30. PubMed ID: 5529474
    [No Abstract]   [Full Text] [Related]  

  • 15. CSF acid monoamine metabolities as a possible reflection of central MAO activity in chronic schizophrenia.
    Bowers MB
    Biol Psychiatry; 1976 Apr; 11(2):245-9. PubMed ID: 971448
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: Self mutilation in Lesch-Nyhan syndrome.
    Mizuno TI; Yugari Y
    Lancet; 1974 Apr; 1(7860):761. PubMed ID: 4132504
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of parkinsonism by amantadine and levodopa.
    Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE
    Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: Huntington's chorea and levodopa.
    Schenk G; Leijnse-Ybema HJ
    Lancet; 1974 Mar; 1(7853):364. PubMed ID: 4131222
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of L-DOPA treatment on brain serotonin metabolism in depressed patients.
    Goodwin FK; Dunner DL; Gershon ES
    Life Sci I; 1971 Jul; 10(13):751-9. PubMed ID: 5142955
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
    Schilkrut R; Rüther E; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):37-42. PubMed ID: 981321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.